The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
CAMMA-2 Cohort A1: Cevostamab in patients with RRMM and prior BCMA-targeted ADC or CAR T-cell therapy
|
CAMMA-2 (NCT05535244) is an ongoing phase I/II study evaluating the efficacy and safety of cevostamab (a FcRH5xCD3 bispecific antibody) in patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class refractory and have received a prior BCMA-targeted agent. Analysis of Cohort A1 (n = 21), which enrolled patients with prior exposure to BCMA-targeted antibody–drug conjugate (ADC) or chimeric antigen receptor (CAR) T-cell therapy, was presented at EHA 2024 by Shaji Kumar. |
| Key learnings: |
|
In CAMMA-2, following treatment with cevostamab, the overall response rate (ORR) for Cohort A1 was 67%, with 38% achieving very good partial response (VGPR). |
|
Response rates were higher in the prior CAR T-cell group (ORR, 73%; VGPR, 55%; n = 11) compared with the prior ADC group (ORR, 60%; VGPR, 20%; n = 10). |
|
Adverse events (AEs) were consistent with the known safety profile of cevostamab, with no fatal AEs. |
|
All cytokine release events were Grade 1–2 and affected 71% of patients overall (90% who received prior ACD and 55% who received prior CAR T-cell therapy). |
|
Cevostamab shows efficacy in heavily pre-treated RRMM patients with prior BCMA-targeted ADC or CAR T-cell exposure, with a clinically manageable safety profile. These findings support further investigation and potential integration of cevostamab into clinical practice for this patient population. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
